FDA Approval Granted to Begin Clinical Trial KoDiscovery, LLC and NewG Lab Pharma, LLC have submitted the comprehensive IND (Investigational New Drug) application to the FDA for approval to begin a unique, combined Phase I/ II-A clinical trial for primary liver cancer.
Three New KOfactor 1 Advanced Products Are Now Available Dr. Ko has further enhanced the already potent KOfactor 1TM formulation by adding proprietary ratios of Resveratrol and Quercetin for even better results. Here is a little information you may find
Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA As of May 1, 2020, NewG Lab Pharma received a letter from the FDA for Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma”. As a result,
Acquired ODD status and License-In for additional Indications As of April 24, 2020, NewG Lab Pharma received the status of Orphan Drug Designation (ODD) for liver cancer and intrahepatic bile duct cancer from KoDiscovery. This acquisition of ODD status
Dietary supplement sales contract with KoDiscovery and Sales started in March NewG Lab Pharma, a 100% U.S. subsidiary of New G Lab, announced on February 14, 2020, that it has signed a KOfactor1 sales contract with KoDiscovery. KOfactor1, the first
Seminars with Georgia Medical Professionals
Seminars about Anti- Bacteria Treatment using 3BP with the University of Wroclaw, Poland.
Medical Week 2019 Baden-Baden, Germany Date: 30 October – 03 November 2019 Venue: Kongresshaus Betriebsgesellschaft mbH, Baden-Baden, Germany Website: http://www.medwoche.de/index.htm – Lecture: Krebskongress – Komplementäronkologie / Cancer Congress – Complementary Oncology – New information about our anticancer technology(03:00 pm – 03:30 pm) – Dr.
2019-05-17 NewG Lab Pharma, Inc. and KoDiscovery, LLC signed the contract : EXCLUSIVE PATENTS LICENSE CONTRACT AND TECHNOLOGY DEVELOPMENT AGREEMENT